BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12024909)

  • 1. Prostate specific antigen as tumor marker: relationship with histologic grading.
    Xess A; Singh M; Raghwendra KH; Sharma HP; Shahi SK
    Indian J Pathol Microbiol; 2001 Jul; 44(3):261-4. PubMed ID: 12024909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
    Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
    Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intraepithelial prostatic neoplasia].
    Stepanov VN; Frank GA; Dzhioev RR
    Urol Nefrol (Mosk); 1999; (1):16-9. PubMed ID: 11149338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
    Goel T; Garg S
    Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Role of prostate-specific antigen in prostatic carcinoma. Validity of an integrated methodologic approach and morpho-biological correlations].
    Tomasino RM; Lo Bianco A; Cacciatore M; Pavone C; Carreca I; Morello V; Salvato M; Florena AM; Pavone-Macaluso M
    Pathologica; 1989; 81(1072):109-26. PubMed ID: 2475847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological features correlation with serum tumour markers in prostatic carcinoma.
    Afzal S; Ahmad M; Mushtaq S; Mubarik A; Qureshi AH; Khan SA
    J Coll Physicians Surg Pak; 2003 Sep; 13(9):511-4. PubMed ID: 12971871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prostate-specific antigen].
    Eide IA; Angelsen A
    Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2528-31. PubMed ID: 11070990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The value of the serum level of the prostate-specific antigen in prostatic pathology].
    Théodon P; Rymer JC; Chopin D; Kouyoudjian JC; Abbou CC; Auvert J
    Ann Urol (Paris); 1988; 22(3):199-205. PubMed ID: 2456713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostate-specific antigen. A new marker of prostatic pathology].
    Boccon-Gibod L; Géraud M; Dugué MA
    Ann Urol (Paris); 1988; 22(3):206-10. PubMed ID: 2456714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostatic specific antigen and prostatic pathology. Value of preoperative blood assay. Preliminary study apropos of 709 case reports].
    Bordes M; Brunet-Lecomte P; Dusserre P; Dusserre-Guion L; Michiels-Marzais D; Morlevat F; Peny J; Roignot P; Colas JM; Ferry N
    Ann Urol (Paris); 1989; 23(4):295-300. PubMed ID: 2480077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M; Tangen CM; Higano C; Schelhammer PF; Faulkner J; Crawford ED; Wilding G; Akdas A; Small EJ; Donnelly B; MacVicar G; Raghavan D;
    J Clin Oncol; 2006 Aug; 24(24):3984-90. PubMed ID: 16921051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia.
    Brimo F; Vollmer RT; Corcos J; Humphrey PA; Bismar TA
    Am J Clin Pathol; 2007 Oct; 128(4):648-51. PubMed ID: 17875517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The usefulness of prostate-specific antigen assay for the early detection and follow up of the prostate cancer].
    Saito Y
    Nihon Rinsho; 1998 Aug; 56(8):1989-93. PubMed ID: 9750493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
    Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of telomerase activity in prostate needle-biopsy samples].
    Wang X; Zhang Y; Ding Q; Ye L; Zhai L; Jia W
    Zhonghua Wai Ke Za Zhi; 1999 Dec; 37(12):762-4. PubMed ID: 11829949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.